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Abstract Data on efficacy and safety of azacitidine in acute
myeloid leukemia (AML) with >30 % bone marrow (BM)
blasts are limited, and the drug can only be used off-label in
these patients. We previously reported on the efficacy and
safety of azacitidine in 155 AML patients treated within the
Austrian Azacitidine Registry (clinicaltrials.gov identifier
NCT01595295). We herein update this report with a popula-
tion almost twice as large (n=302). This cohort included 172
patients with >30 % BM blasts; 93 % would have been
excluded from the pivotal AZA-001 trial (which led to
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European Medicines Agency (EMA) approval of azacitidine
for high-risk myelodysplastic syndromes (MDS) and AML
with 20–30 % BM blasts). Despite this much more unfavor-
able profile, results are encouraging: overall response rate was
48 % in the total cohort and 72 % in patients evaluable
according to MDS-IWG-2006 response criteria, respectively.
Median OS was 9.6 (95 % CI 8.53–10.7)months. A clinically
relevant OS benefit was observed with any form of disease
stabilization (marrow stable disease (8.1 months), hematolog-
ic improvement (HI) (9.7 months), or the combination thereof
(18.9 months)), as compared to patients without response and/
or without disease stabilization (3.2 months). Age, white
blood cell count, and BM blast count at start of therapy did
not influence OS. The baseline factors LDH >225 U/l, ECOG
≥2, comorbidities ≥3, monosomal karyotype, and prior
disease-modifying drugs, as well as the response-related fac-
tors hematologic improvement and further deepening of re-
sponse after first response, were significant independent pre-
dictors of OS in multivariate analysis. Azacitidine seems
effective in WHO-AML, including patients with >30 % BM
blasts (currently off-label use). Although currently not
regarded as standard form of response assessment in AML,
disease stabilization and/or HI should be considered sufficient
response to continue treatment with azacitidine.
Keywords AustrianAzacitidine Registry . Azacitidine .
AML . Overall survival . Prognostic factors . Bonemarrow
blasts
Introduction
Acute myeloid leukemia (AML) is an aggressive disease with
an unfavorable prognosis [1, 2]. Treatment with curative
potential, i.e., conventional chemotherapy and/or allogeneic
stem cell transplantation, is rarely an option for elderly pa-
tients due to high age, comorbidities, poor performance status,
and/or adverse cytogenetics. Azacitidine is approved for AML
with 20–30 % bone marrow (BM) blasts. Approval was based
on the pivotal AZA-001 trial [3, 4]. Currently, the 001-follow-
up trial (clinicaltrials.gov identifier NCT01074047) is under-
way with the same design, but limited to patients with >30 %
BM blasts, with the aim to widen the indication of azacitidine
to AML patients as defined by WHO, i.e., irrespective of BM
blast count. Until the results of this trial become available,
treatment of AML patients with more than 30 % BM blasts
with azacitidine remains an off-label use.
We previously reported on the use, efficacy, and safety of
azacitidine in 155 WHO-AML patients treated in a real-life
setting. We herein update this report with a population almost
twice as large (n=302). The aim of the current publication was
to potentially confirm, consolidate, and validate our previous
results. The primary endpoint was evaluation of efficacy (i.e.,
response) of azacitidine in patients with AML defined accord-
ing to WHO criteria (including patients with >30 % BM
blasts). The secondary endpoints were safety (i.e., toxicity
and adverse events), overall survival (OS), and statistical anal-
ysis of factors known or thought to influence overall survival in
order to establish prognostic markers (Table 1 [4–14]).
Patients, design, and methods
Between February 2009 and October 2013, 302 AML patients
from 14 specialized centers for hematology and medical on-
cology in Austria were included. Data cleaning/survival anal-
ysis cutoff date was 21 January 2014. The sole inclusion
criteria were the diagnosis of WHO-AML and treatment with
at least one dose of azacitidine. No formal exclusion criteria
existed, as the aim was to include all AML patients treated
with azacitidine, irrespective of age, comorbidities, and/or
number of previous lines of treatment. Informed consent to
allow the collection of personal data was obtained for all
retrospectively documented patients who were alive, as well
as for all prospectively included patients.
Registry design, data collection and monitoring, as well as
assessment of efficacy, safety and endpoints within the Aus-
trian Azacitidine Registry were performed as previously de-
scribed [8, 15].
Overall response was defined as complete response (CR),
marrow complete response (mCR), partial response (PR) (as
defined by commonly used AML response criteria [16]), and
hematologic improvement (HI) (as defined by the IWG-MDS-
2006 response criteria [17]). Marrow stable disease (mSD)
was defined as failure to achieve at least PR, but no evidence
of progressive disease (PD) for >8 weeks. PD was defined as
any of the following: (i) ≥50 % decrement from maximum
remission/response in granulocytes or platelets, (ii) reduction
in hemoglobin by 2 g/dl, (iii) transfusion dependence [17].
OS was assessed using the Kaplan–Meier method. Univar-
iate analyses were performed with log-rank tests. Cox regres-
sion stratified on the various factors was used for analyses of
risk factors for OS. Baseline characteristics were compared by
nonparametric tests (Chi-squared test for qualitative variables,
Wilcoxon test for quantitative variables). For multivariate
analysis, logistic regression according to the Wald method
with forward stepwise selection (entry level 0.05; level for
keeping the variable 0.051) was used. Univariate analyses
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were performed and confirmed by two independent statisti-
cians [H.A., O.E.]. The confirmed results were the basis for
multivariate analysis. All variables with p<0.05 in univariate
analyses were included in multivariate analysis, except for
those cases, where parsimony would have been disrupted
due to redundancy in the variables. Analyses were performed
with SPSS. No adjustments were made for multiple testing.
Results
Patient characteristics
Patient baseline characteristics at azacitidine treatment start
can be taken from Table 2. Median age was 73 (range 30–93);
43 % of patients were older than 75, 21 % were older than 80,
and 8 % were older than 85 years, respectively; 172 patients
(57 %) had >30 % BM blasts; 19 % had an unfavorable
karyotype, and 67% had an intermediate karyotype according
to MRC criteria [18]. In the absence of consensus for cytoge-
netic classification of AML in the elderly [4, 19], we addi-
tionally assessed the IPSS cytogenetic risk categories [20]
(Table 2).
Treatment modalities
Azacitidine was administered as first-line treatment in 46% of
patients; 46 % of patients received azacitidine after insuffi-
cient response to, or early relapse after, conventional
chemotherapy/allo-SCT (32 %), or other disease modifying
treatment (14 %); the remaining patients received azacitidine
either as bridging to allogeneic stem cell transplantation (allo-
SCT) (3 %) or as maintenance treatment after CR to chemo-
therapy (4 %). Azacitidine was not always first-line therapy,
but also second-, third-, fourth-, fifth-, or last-line therapy for a
relevant proportion of our patients: 28 % had received more
than one line of conventional chemotherapy prior to
azacitidine (Table 2).
A median number of 4 (range 1–37) azacitidine courses
were given. Most patients (85 %) received the drug subcuta-
neously (average dose/cycle, 846 mg), 10 % intravenously
(average dose/cycle, 815 mg), and in 5 % both applications
forms were used (average dose/cycle, 831 mg); 77 % of
patients predominantly received 7 days of azacitidine (53 %
European Medicines Agency (EMA)-approved d1-7 (median
dose/cycle, 924 mg), 24 % 5-2-2 (median dose/cycle,
910 mg)) (Supplemental Table 1). EMA-approved azacitidine
target dose (75 mg/m2×7±10 %) was reached in 33 % of
applied cycles; 349/2013 (17 %) of all cycles were adminis-
tered as “flat” dosage (i.e., 100 mg azacitidine/cycle-day;
median dose/cycle, 700 mg). Hospitalization for the sole
reason of azacitidine application occurred in 47 % of cycles
at the discretion of the treating physician, mainly due to
Table 2 Baseline characteristics at azacitidine treatment start
Median age, years (range) 73 (30–93)
Gender, male, n (%) 175 (57.9)
WHO diagnosis, n (%)a, b
t-AML 24 (7.9)
AML-RCAc/gene mutationsd 61 (20.2)
AML-RCA 13 (4.3)
AML with gene mutations 52 (17.2)
AML-MRF 203 (67.2)
AML-MRC 75 (22.2)
AML with antecedent hematologic disease 89 (29.5)
Antecedent MDS 60 (19.9)
Antecedent CMML 11 (3.6)
Antecedent CMPD 18 (6.0)
AML with myelodysplasia (MLD) 173 (57.3)
AML-NOS 61 (20.2)
Peripheral blood blasts, n (%)
No data 14 (4.6)
0 % 101 (33.4)
>0 % 187 (61.9)
Median (range), % 3.5 (0–97)
Bone marrow blasts, n (%)
<20 %e 51 (16.9)
20–30 % 79 (26.2)
>30 % (off-label use) 172 (57.0)
Median (range), % 32 (0–98)
WBC count, n (%)
<10 G/l 150 (49.7)
≥10 G/l 61 (20.2)
≥15 G/l 40 (13.2)
≥20 G/l 29 (9.6)
≥30 G/l 15 (5.0)
≥50 G/l 7 (2.3)
Transfusion dependence, n (%)
Any type of TD 183 (60.6)
RBC-TD 175 (57.9)
PLT-TD 113 (37.4)
RBC-TD + PLT-TD 105 (34.8)
IPSS cytogenetic risk, n (%)




MRC cytogenetic risk, n (%)




Specific chromosomal aberrations, n (%)
Not evaluable/not evaluated 33 (10.9)
Normal karyotype 149 (49.3)
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concerns with frailty and potential toxicity, and due to logistic
reasons for patients living far away from the hospital.
Azacitidine treatment dose was modified during treatment in
18 % of patients: dose reductions occurred due to an adverse
Table 2 (continued)
Median age, years (range) 73 (30–93)
Specific aberrationsb 120 (39.7)
Complex karyotype 31 (10.3)
Monosomal karyotype 32 (10.6)
MK only 6 (2.0)








Molecular diagnosticsb, n (%)








Renal insufficiency 54 (17.9)
Diabetes mellitus 54 (17.9)
Solid tumor 41 (13.6)
Liver disease 35 (11.6)
Pulmonary 33 (10.9)
Hematologic neoplasmf 31 (10.3)
Thromboembolic episodes 28 (9.3)
Infection 28 (9.3)
Obesity (BMI >35 kg/m2) 25 (8.3)
Cerebrovascular disease 25 (8.3)
Psychiatric disturbance (requiring consult/treatment) 20 (6.6)
Rheumatologic 11 (3.6)
Peptic ulcer (requiring treatment) 8 (2.6)
Inflammatory bowel disease 3 (1.0)






ECOG ≥2, n (%) 73 (24.2)
HCT-CI, n (%)
Low risk 93 (30.8)
Int. risk 117 (38.7)
High risk 92 (30.5)
Treatment prior to AZAg, n (%)
None 115 (38.1)
Growth factors and/or iron chelators 24 (7.9)
Table 2 (continued)
Median age, years (range) 73 (30–93)
Prior disease modifying treatment 163 (54.0)
Treatment prior to AZAb, n (%)
None 115 (38.1)
Erythropoietin stimulating agents 23 (7.6)
G-CSF 34 (11.3)
Thrombopoietin-stimulating agents 2 (0.7)
Iron chelation therapy 12 (4.0)
Thalidomide 5 (1.7)
Lenalidomide 11 (3.6)
ATG, CyA 4 (1.3)
Low-dose cytarabine 13 (4.3)
Intensive chemotherapy for MDS/AML 125 (41.4)
Chemotherapy for other neoplasm 22 (7.3)
Hydroxyurea 26 (8.6)
Others 14 (4.6)
Reason for treatment, n (%)
1st line treatmenth 139 (46.0)
Bridging to allo-SCT 10 (3.3)
Maintenance after CR to CTX 13 (4.3)
No CR to conventional chemotherapy/allo-SCT 98 (32.5)
No CR to other disease modifying treatment 42 (13.9)
t-AML treatment-related AML, AML-RCA AML with recurrent cytoge-
netic abnormalities, AML-MRFAMLwithMDS-related features,CMPD,
chronic myeloproliferative disease, AML-NOS AML not otherwise spec-
ified, MP myeloproliferative, COPD chronic obstructive pulmonary dis-
ease, NHL non-Hodgkin’s lymphoma, ECOG Eastern Cooperative On-
cology Group
a If a patient fulfilled criteria for more than oneWHO category, weighting
was performed as follows: t-AML > AML-RCA > AML-MRF
bAmounts to >100 % due to multiple choice nature
c Includes the following structural abnormalities: inversion 16, t(8;21),
t(15;17), t(9;11), t(6;9), t(1;22)
d Includes mutations in FLT3, NPM1, and/or CEBPα
e Includes arrhythmia (atrial fibrillation or flutter, sick sinus syndrome, or
ventricular arrhythmias), coronary artery disease, coronary heart disease,
myocardial infarction or ejection fraction ≤50 %, and/or valvular heart
disease (except mitral valve prolapse)
f Includes monoclonal gammopathy of unknown significance, multiple
myeloma, low-grade NHL, high-grade NHL, M. Hodgkin, Burkitt’s
lymphoma, chronic myeloid leukemia, hypereosinophilic syndrome,
chronic myeloproliferative diseases, and others
g BM blast count was <20%, in those patients with established AMLwho
were refractory to -or had no CR after-conventional chemotherapy or
allogeneic stem cell transplantation
hDefined as patients without prior disease modifying treatment (i.e.,
growth factors and iron chelation were allowed)
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event (15 %) or due to patient’s/physicians wish (2 %); dose
escalation was performed in 1 % of patients. Dose reductions
were performed in 32 % of responding patients (prior to best
response (13 %), at best response (3 %), or after best response
(15 %)).
Concomitant treatment and best supportive care measures
Erythropoietin-stimulating agents (ESA) (2.4 %), iron chela-
tion treatment (ICT) (2.3 %), and G-CSF (18.4 %) were given
in parallel to azacitidine when deemed necessary by the
treating physician.
Response
Overall response, defined as CR, mCR, PR, and HI, was
documented in 48% of the total intention-to-treat (ITT) cohort
and in 72 % of patients evaluable according to MDS-IWG-
2006 response criteria [17] (i.e., had received >2 cycles of
azacitidine); HI was documented in 40 % (ITT) and 72 %
(evaluable according to IWG, i.e., had received >2 cycles of
azacitidine), respectively; CR/mCR was achieved in 17 % of
the ITTcohort and in 28% of patients in whom a BM aspirate/
biopsy was performed (Supplemental Table 2).
The median number of cycles received by responding
patients was 8.5 (range 1–37), and 2 (range 1–28) in non-
responders (included patients with SD). Of note, the distribu-
tion of applied schedules as well as the median and mean
azacitidine dosages/cycle did not differ between responders
and non-responders.
Time to response and response deepening
Median time to first response was 3.0 months. First response
occurred after 3, 4, and 5 cycles in 58, 79, and 88 % of
responding patients, respectively, but could be observed as
late as cycle 16 in patients with stable disease who were kept
on therapy. First response was best response in 99/144 patients
(69 %). Median response duration was 3.4 (range 0.3–33.0)
months. Further deepening of response after first response
(i.e., achievement of BM blast reduction in terms of mCR/
CR/PR after HI) was seen in 45/144 (31 %) of responders.
Best response was reached by cycle 9 in 94 %, but could be
observed as late as cycle 21. Median time from first to best
response was 3.5 (range 0.8–21.5)months.
Toxicity and adverse events
A total of 1.031 adverse events (AE) were documented in
2.013 azacitidine cycles. Overall, 24 % of all AE and 20 % of
grade 3–4 (G3-4) AE were attributed to azacitidine (Supple-
mental Table 3). Of all AE, 22 % resulted in hospitalization
and 9 % resulted in death. Most AE had no consequence for
azacitidine treatment (66 %). Dose reduction (5 %), treatment
pause (11 %), prolongation of azacitidine cycle duration
>28 days (7 %), and/or termination of azacitidine treatment
(11 %) were not commonly necessary.
G3-4 hematologic toxicity occurred in 48 %: G3-4 neutro-
penia, thrombocytopenia, and anemia were documented in 35,
30, and 28 % of patients, respectively; clinically relevant
bleeding events were noted in 12 % of patients (Table 3).
Non-hematologic toxicity was usually mild, the most com-
mon AE being fatigue (39 %), gastrointestinal (38 %), un-
specified pain (30 %), and injection site reactions (22 %).
Infectious complications of any grade were documented in
63 %, febrile neutropenia in 19 % (Table 3). G3-4 infectious
events occurred in 33 % and were dominated by pulmonary
infections, sepsis, and fever of unknown origin. Hospital
admission was required in 173/423 (41 %) and transfer to an
intensive care unit was necessary in 3 % of total infectious
events. Treatment with G-CSF, antibiotics, antifungals, and/or
virostatics occurred in 18, 86, 22, and 14 %, respectively.
A total of 47 non-hematologic G3-4 events occurred in 33
patients (11 %): 39 (83 %) of these grade 3–4 events occurred
in the cardiac system: left ventricular output failure (n=23),
arrhythmia (n=7), hypertension (n=5), myocardial infarction
(n=3), angina pectoris (n=1). In 20/33 (61 %) patients
experiencing cardiac G3-4 events, pre-existing coronary ar-
tery disease, reduced cardiac function, arrhythmias, and/or
valvular heart disease were documented prior to azacitidine
treatment and worsening was not thought to be azacitidine-
related.
Overall survival and potential prognostic parameters
Median OS was 9.6 (95 % CI 8.53–10.7)months as from
initiation of treatment with azacitidine in the entire cohort.
Median progression-free survival in responding patients was
9.1 (0.9–39.9)months. Progression defining events were death
due to any reason, disease progression, disease relapse after
response, and/or new cytogenetic aberration/clonal evolution.
Median OS was 16.1 months for responders (defined as CR/
mCR/PR/HI) and 3.7 months for non-responders. Median
time from first diagnosis to treatment start with azacitidine
for untreated (n=139) versus pre-treated with disease-
modifying treatment (n=163) patients was 0.6 and 7.1months,
respectively. Median time from azacitidine treatment stop to
death was 1.9 months in the entire cohort. Reasons for cessa-
tion of azacitidine in patients receiving ≤2 cycles of
azacitidine (n=101, 33.4 %) were death (n=48), disease pro-
gression (n=20), patient’s wish (n=9), toxicity or recurrent
infectious complications (n=5), allo-SCT (n=2), and others
(n=13); 41/101 receiving ≤2 cycles died within 1 month of
treatment termination, and a further 35 died within 6 months.
In line with our previous results [8], the following baseline
factors did not significantly affect overall survival: gender, age
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</≥75, age </≥80, WHO-AML-type, WBC count </≥10 G/l,
WBC count </≥15 G/l, WBC count </≥30 G/l, neutrophil
count <1,000/μl, lymphocyte count <2,000/μl, RBC-TD,
BM blast count ≤30/>30% (irrespective of whether the whole
cohort or only patients treated with azacitidine first line were
analyzed), serum erythropoietin level, as well as prior treat-
ment with ESA, G-CSF, iron chelators, low-dose Ara-C, or
hydroxyurea (Supplemental Table 4 and Fig. 1a–h). When
looking at responding patients only, WHO-AML type, WBC
count, and treatment according to EMA label had no signifi-
cant effect on survival (Supplemental Table 4).
Time-dependent factors that did not affect overall survival
include the following: EMA target dose (p=0.213), treatment
schedule, dose/cycle, and platelet-doubling after one cycle (Sup-
plemental Table 4). The following toxicity and adverse events-
related factors had no effect on overall survival: bleeding events,
febrile neutropenia, surgery, non-hematologic toxicity, falls, and
pain due to any reason (Supplemental Tables 1 and 4).
In multivariate analysis, the following baseline factors
remained independent adverse predictors for OS: LDH
>225 U/l, ECOG ≥2, number of comorbidities (as predefined
by the HCT-CI [21]) >3, and monosomal karyotype. The
following treatment-related factors that remained independent
predictors for OS in multivariate analysis were as follows:
AZA first-line treatment, hematologic improvement, and fur-
ther deepening of response after first response; best marrow
response (p=0.642) did not meet the 0.05 significance level
for inclusion in the multivariate analysis; azacitidine pause
due to adverse events was associated with longer OS in
multivariate analysis; dose reduction due to adverse events
(p=0.051) and fatigue limiting self-care (p=0.053) were bor-
derline significant in multivariate analysis (Figs. 2 and 3, and
Supplemental Table 5).
Table 3 Specific adverse eventsa






G3-4 145 (48.0) 330
Thrombopenia G3-4 91 (30.1) 195
Neutropenia G3-4 105 (34.8) 223
Anemia G3-4 84 (27.8) 177
Bleeding events – 35 (11.6) 60
Febrile neutropenia – 56 (18.5) 95
Infectious
complications
G1-2 91 (30.1) 311
G3-4 100 (33.1) 112
Non-hematologic toxicity
Liver G1-2 2 (0.7) 3
G3-4 2 (0.7) 2
Kidney G1-2 12 (4.0) 12
G3-4 3 (1.0) 3
Heartc G1-2 8 (2.6) 14
G3-4 29 (9.6) 34
Blood pressure G1-2 3 (1.0) 3
G3-4 5 (1.7) 5
Metabolic G1-2 4 (1.3) 4
G3-4 0 (0.0) 0
Thromboembolic G1-2 11 (3.6) 12
G3-4 2 (0.7) 2
Neurologic G1-2 19 (6.3) 26
G3-4 2 (0.7) 2
Nausea G1-2 33 (10.9) 46
G3-4 1 (0.3) 1
Vomiting G1-2 9 (3.0) 12
G3-4 0 (0.0) 0
Constipation G1-2 21 (7.0) 28
G3-4 1 (0.3) 1
Diarrhea G1-2 26 (8.6) 35
G3-4 0 (0.0) 0
Gastrointestinal,
others
G1-2 24 (7.9) 31
G3-4 0 (0.0) 0
Injection site
reaction
G1-2 64 (21.2) 123
G3-4 2 (0.7) 2







Pain Mild 43 (14.2) 82
Moderate 39 (12.9) 51
Severe 9 (3.0) 9
Surgery Elective 19 (6.3) 23
Table 3 (continued)




Emergency 10 (3.3) 11
Fall Total 26 (8.6) 29




Novel solid tumor Yes 3 (1.0) 3
a Assessed according to NCI Toxicity Criteria (http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/ctc.htm) and Common
Terminology Criteria for AE (CTCAEv.4) (http://evs.nci.nih.gov/ftp1/
CTCAE/About.html)
b Grade 3–4 cytopenias reported, are those that were documented as
adverse events, and thus felt to be a worsening of pre-existing cytopenia
by the respective treating physicians
c Reported cardiac AE were left ventricular output failure (n=23), arrhythmia
(n=7), hypertension (n=5), myocardial infarction (n=3), angina pectoris (n=1)
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Discussion
This is the largest so far published number of azacitidine-
treated WHO-AML patients, with the highest per capita cov-
erage of AML patients in a nationwide registry, suggesting
limited selection (Table 1, Supplemental Table 7). Data on the
efficacy of azacitidine in AML with >30 % BM blasts are
limited, and the drug can only be used off-label in these
patients (Table 1 [4–14]). We report on 302 WHO-AML
patients treated with azacitidine. This cohort included 172
Fig. 1 Kaplan–Meier curves of
baseline factors that did not affect
overall survival (OS). a Effect of
bone marrow blast count on OS
(total cohort). b Effect of bone
marrow blast count on OS (AZA
first line). c Effect of age on OS. d
Effect ofWHO-AML type onOS.
e Effect of white blood cell
(WBC) count on OS. f Effect of
WBC </≥15 G/l on OS. g Effect
of achievement of EMA/FDA-
target dose on OS. h Effect of
azacitidine (AZA) schedule: 5 vs.
7 days of azacitidine per cycle on
OS
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patients with >30 % BM blasts (Tables 1 and 4 [6–8, 12, 14]).
The number of AML diagnoses per year, as well as the
number of AML patients included in the respective year for
Austria in general and Salzburg in particular, is presented in
Supplemental Table 7 (data obtained from Statistics Austria
(personal communication 23 May 2014), and Tumor Registry
Salzburg (personal communication 26 May 2014)).
In order to exclude a potential time-dependent bias regard-
ing both the choice of AML patients for treatment with
azacitidine, as well as inclusion in the Austrian Azacitidine
Registry, we compared all relevant baseline characteristics,
treatment modalities, as well as response rates, and the occur-
rence of adverse events of our previously published cohort
(n=155; data cutoff 21 January 2012) [8] with the current
cohort (n=302, data cut off 21 January 2014). No significant
difference could be found for any of these characteristics
(Supplemental Table 6).With this nearly twice as large cohort,
we confirm and validate the safety and efficacy of azacitidine
in WHO-AML patients treated in a real-life setting. The
observed median OS of 9.6 months and the high overall
response rates (48 % ITT) seem remarkable, particularly since
(i) the registry included many elderly (43 % ≥75 years),
comorbid (79 %), and/or pretreated patients (62 %); (ii)
33 % of patients received ≤2 cycles of azacitidine (reasons
therefore listed in the “Results” section); (iii) 82 % of our
registry population would have been excluded from the AZA-
001 registration trial due to an estimated life expectancy
<3 months, ECOG >2, t-AML, prior treatment, or planned
allo-SCT [3, 4]. If BM blast count >30 % is also taken into
account, 93 % would have been excluded.
Furthermore, virtually all of our prior results [8] regarding
the statistical value of various factors on OS are confirmed by
the present analysis. Slight discrepancies are mentioned below
and in Table 4. In addition to the parameters looked at previ-
ously, we analyzed the putative prognostic effect of platelet-
doubling after cycle 1, monosomal karyotype, and disease
stabilization, as these factors have emerged to be of interest
only recently [12, 13, 22].
This is the first report to analyze the effect of platelet-
doubling after cycle 1 on OS in AML patients treated with
azacitidine. Statistical significance was not observed (Supple-
mental Table 4).
We confirm the recently introduced monosomal karyotype
(MK) [23] to be the strongest adverse cytogenetic predictor
for OS (even outperforming the categories “complex karyo-
type” and “MDS-related cytogenetic abnormalities” [22–24])
(Figs. 2 and 3a–b, Supplemental Table 5). We extend these
findings to the new WHO classification and show that
azacitidine cannot overcome the adverse outcome conferred
by the presence of MK. Outcome in patients with MK is not
only dismal with azacitidine but also with induction therapy
and/or allogeneic stem cell transplantation [22]. Therefore,
clinical trials are urgently needed for this patient subgroup.
We confirm our previous results [8] that a certain amount of
aplasia induction seems necessary before response occurs, and
that further deepening of response after first response (i.e.,
achievement of BM blast reduction in terms of mCR/CR/PR
after HI) translates into significantly longer OS (21.4 months),
compared with patients for whom first response was best
response (12.6 months) (Figs. 2 and 3e, Supplemental
Table 5). This underlines the importance of continuing
azacitidine treatment if or whenHI occurs, even in the absence
of marrow response. Patients experiencing HI had significant-
ly longer OS than those who did not (16.1 vs. 4.5 months)
(Fig. 3d and Supplemental Table 5). This is the first report to
separately analyze HI and marrow response in multivariate
0 1.5 2.0 2.5 3.01.00.5 3.5 4.0
Covariates  Forest plot HR & 95% CI p-value
LDH 1.349 (1.038–1.754) 0.025
≤225 U/l vs >225 U/l
ECOG performance score 1.429 (1.046–1.952) 0.025
  <2 vs ≥2
Number of comorbidities 1.740 (1.304–2.322) <0.001
≤3 vs >3
Monosomal karyotype 1.293 (1.096–1.526) 0.002
  No vs Yes
AZA 1st line 1.103 (1.019–1.194) 0.015
No vs Yes
Hematologic improvement (IWG) 0.675 (0.462–0.986) 0.042
  No vs Yes
Response deepening 0.398 (0.324–0.490) <0.001
  No response
  vs 1st response = best response 
  vs 1st response < best response
Infectious complications 1.772 (1.323–2.374) <0.001
  None/Grade 1–2 vs Grade 3–4
Hematologic toxicity Grade 3–4 0.647 (0.486–0.861) 0.003
  No vs Yes
AZA pause due to adverse events 0.543 (0.393–0.749) <0.001








Fig. 2 Forrest plot of factors
significantly influencing overall
survival of azacitidine-treated
AML patients (n=302) in
multivariate analysis
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analysis. The former remained an independent prognostic
factor for OS in multivariate analysis, whereas the latter did
not (Fig. 2 and Supplemental Table 5). This seems of clinical
relevance, as hematologic improvement is not generally con-
sidered sufficient response in AML patients. Very recently, the
French group reported no survival benefit for patients achiev-
ing HI in addition to stable disease [12]. However, the authors
state that (i) only those patients not achieving mCR/CR/PR
were analyzed for HI; (ii) HI was only assessed when patients
were evaluable for these parameters; (iii) it is not stated how
many patients were not evaluable for HI or how SD was
defined (i.e., marrow SD or hematologic SD). In our cohort,
OS was significantly better for patients achieving mCR/CR/
PR with HI (20.5 months), followed by mSD with HI
(18.9 months), mCR/CR/PR without HI (15.0 months), HI
without mSD (9.7 months), mSD without HI (8.1 months),
and not unexpectedly, OS was worst for patients with progres-
sive disease or who received less than 3 cycles of azacitidine
(3.2 months) (Supplemental Table 5). We thus confirm and
extend the observations of the French group [12] as follows: It
seems that achievement of any form of disease stabilization,
be it mSD or HI alone, and especially the combination thereof
(without the requirement of concomitant BM blast reduction,
but with the minimal requirement of mSD), is sufficient to
confer a clinically relevant OS benefit. In our opinion and
clinical experience, we thus consider disease stabilization to
be sufficient “response” to continue treatment with
azacitidine, although we are aware of the fact that this is
currently not regarded as a standard form of response assess-
ment in AML (Fig. 3f). In our experience, disease stabilization
is lost rapidly once treatment with azacitidine is stopped
(median time to death, 1.9 months). Thus bearing the lack of
Fig. 3 Kaplan–Meier curves of
baseline factors that significantly
affected overall survival (OS) in
multivariate analysis. a Effect of
monosomal karyotype (MK) on
OS. b Effect of MK in
comparison to complex karyotype
on OS. c Effect of prior disease-
modifying treatment (i.e.,
azacitidine first-line no vs. yes) on
OS. d Effect of hematologic
improvement (HI) on OS. e Effect
of response deepening (i.e.,
achievement of BM blast
reduction in terms of mCR/CR/
PR after HI) on OS. f Overall
survival by best response
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therapeutic alternatives in mind, we continue azacitidine treat-
ment until overt clinical disease progression.
In order to facilitate the comparison of our previous and
current results with data obtained from much smaller cohorts,
we provide an in-depth comparison of all published multivar-
iate analyses on putative prognostic factors for OS of WHO-
AML patients treated with azacitidine (including results from
the present study) (Table 4). Only one baseline factor
remained a significant adverse predictor for OS in all multi-
variate analysis (4/4) in which baseline factors were analyzed,
namely ECOG/WHO performance score (Table 4). Thus, the
ability of patients to function in everyday life seems to be the
most important predictor of OS in elderly AML patients
treated with azacitidine. In line with this, the absolute number
of comorbidities, which was borderline significant in our
previously published smaller cohort of AML patients (n=
155) [8], was confirmed to be an independent adverse predic-
tor of OS in our larger present cohort (n=302) (Fig. 2, Table 4,
and Supplemental Table 5).
Although not unexpected, we show for the first time in
multivariate analysis—thus confirming our clinical experi-
ence and notion—that prior disease-modifying treatment is
an adverse predictor of OS for AML patients treated with
azacitidine. In multivariate analysis, patients receiving
azacitidine first line had significantly longer overall survival
than pretreated patients (12.9 vs. 7.5 months) (Figs. 2 and 3c,
Supplemental Table 5).
Age, gender, AML type, and transfusion dependence prior
to azacitidine had no significant effect on OS in all reports in
which these factors were analyzed (Table 4, Supplemental
Table 4, and Fig. 1c, d). As azacitidine is still not approved
for the treatment of AML patients with >30 % BM blasts, we
Table 4 Comparison of prognostic factors for OS in multivariate analysis (MVA) of all full publications on azacitidine treated AML patients
Variable Italy Holland Lausanne France Austria Present study
n AML patients 82 55 38a 149 155 302
n AML patients with >30 % BM
blasts
49 17 29 87 98 172
Prognostic factors for OS
Age No MVA for OS
performed
ND No No No No
Gender ND No No No No
Cytogenetic risk group Yes (**p=0.001)b, c Nod Yes (**p<0.001)b Nob Nob
Monosomal karyotype ND ND ND ND Yes (**p=0.002)
WBC </≥15 g/l Yes (**p=0.003)e ND Yes (**p=0.001) No No
LDH </≥225 IU/l No ND ND No Yes (*p=0.025)
ECOG performance score </≥2 Yes (**p=0.006)f ND Yes (**p=0.006) Yes (*p=0.040) Yes (*p=0.025)
Number of comorbidities </≥4 ND ND ND No (p=0.086) Yes (**p<0.001)
AZA first line ND ND ND ND Yes (*p=0.015)
AML typeg No Noh No No No
BM blasts </≥30 % No No No No No
PB blasts </≥0 % No Noi ND Yes (*p=0.040) No
Transfusion dependence No Yes (**p=0.009)j ND No No
RBC-TI ND ND Yes (**p<0.001) Yes (*p=0.042)
PLT-TI ND No ND
Hematologic improvement ND ND ND
AZA schedule (5 vs. 7 days) ND ND No No No
AZA dose (</=75 mg/m2/day) ND ND No No No
a Baseline characteristics were reported from 52 patients, but only 38 were evaluated for response
bDefined according to MRC classification
c Only the poor risk-group predicted OS, the good vs. intermediate risk group did not (p=0.91)
d Defined according to the HOVON classification
e Cutoff, </>10 G/l; however, this variable was not significant in univariate analysis (p=0.11)
f According to WHO performance score
g Primary AML, post-MDS, post-MPN, refractory/relapsed disease or therapy-related AML
hOnly therapy-related AML (n=10 patients) had an impact when looked at separately (**p<0.001), whereas AML type did not (p=0.086)
i PB blast cut off of ≥20 % used
j Not reported on separately, i.e., patients that were transfusion independent at baseline, or who achieved RBC-TI during treatment were grouped together
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were particularly interested to see that the percentage of BM
blasts had no significant effect on OS in this off-label treated
patient subgroup (n=172), which is in line with observations
by others with smaller patient numbers (Fig. 1a, b, Table 4,
and Supplemental Table 4).
The present report confirms that WHO-AML type does not
seem to adversely predict OS.We conclude that AML patients
with MDS-related features, or therapy-related AML, should
not be precluded from treatment with azacitidine. The latter
seems clinically relevant, especially in light of the fact that
these AML subgroups are generally considered to have worse
prognosis and to be less responsive to conventional
chemotherapy.
The prognostic relevance of elevated WBC ≥15 G/l cur-
rently remains unclear and conflicting results exist (Table 4).
Several statistical issues remain open in the two publications
describing a significant adverse effect of WBC ≥15 G/l on OS
in multivariate analysis: (i) in the Dutch cohort, this variable
was not significant in univariate analysis (p=0.11), but was
nevertheless included in multivariate analysis. Furthermore,
95 % CI were not given for multivariate results [14]; (ii) the
univariate p values used for entry of the variables into the
multivariate model (p<0.15 [14] and p<0.85 [25], respective-
ly) were less stringent than in the present publication
(p<0.05), which could not find an adverse effect of elevated
WBC, irrespective of which cutoff value was used (</≥10, </
≥15, or </≥30 G/l (Supplemental Table 4 and Fig. 1e, f)).
Neither azacitidine schedule (5 vs. 7 days) nor dosage (<vs.
= 75 mg/m2/day) had a significant effect on OS in 3/3 reports
in which these factors were analyzed (Table 4, Supplemental
Table 4, and Fig. 1g, h). Thus, alternative schedules and
dosages seem safe and without loss of efficacy, and receiving
the drug regularly and continuously until overt clinical pro-
gression occurs is likely more relevant than the absolute
dosage per day or number of days per cycle.
In conclusion, we confirm that azacitidine is safe and
effective in elderly, comorbid AML patients treated in an
everyday life setting, irrespective of BM blast count.
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